ARS Pharma Wins Canada Nod for Needle-Free Epinephrine

San Diego, U.S. | April 15, 2026

ARS Pharmaceuticals has achieved a major regulatory milestone with Health Canada approval of neffy® (epinephrine nasal spray), marking the first needle-free emergency treatment for anaphylaxis available in the country. This approval represents a significant advancement in pharmaceutical innovation and patient-centric drug delivery, offering a non-invasive alternative to traditional epinephrine auto-injectors for both adults and pediatric patients weighing 30 kg or more. The therapy is designed to address critical gaps in emergency allergy treatment, where delays in administration can lead to severe outcomes, and highlights the growing importance of accessible, easy-to-use drug formulations in real-world healthcare settings.

Health Canada Approval Marks Major Pharma Milestone

The approval of neffy underscores a key regulatory breakthrough in the Pharma sector, as Health Canada recognizes the clinical need for improved delivery methods in anaphylaxis management. Epinephrine remains the only approved first-line treatment for severe allergic reactions, yet traditional auto-injectors have long faced limitations including needle anxiety, portability challenges, and incorrect usage.

neffy addresses these barriers by delivering intranasal epinephrine through a simple, compact, and needle-free device, enabling faster and more reliable administration during emergencies. This advancement is expected to significantly improve patient compliance, adherence, and timely intervention, especially in high-risk populations where hesitation or improper device use has historically reduced treatment effectiveness.

Needle-Free Innovation Transforms Emergency Allergy Care

The introduction of neffy reflects a broader shift toward patient-centric pharmaceutical innovation, where usability and accessibility are prioritized alongside clinical efficacy. The nasal spray offers several advantages, including rapid drug absorption, ease of administration, extended shelf life, and temperature stability, making it suitable for real-world emergency conditions.

Importantly, the device eliminates the need for injection training, reducing dependency on caregivers and increasing the likelihood of immediate administration. Evidence indicates that many patients delay or avoid using injectable epinephrine due to fear or complexity, and neffy directly addresses this gap by enabling quick, confident, and needle-free treatment, thereby improving overall patient outcomes.

Global Commercial Expansion and GMP Readiness

The Canadian approval also highlights the global commercialization strategy of ARS Pharmaceuticals, with neffy already available in the United States and approved in China. The company has partnered with ALK-Abelló A/S to support distribution in Canada, with commercial availability expected by summer 2026. From a regulatory and manufacturing standpoint, this milestone demonstrates strong GMP compliance, validated production processes, and scalable manufacturing capabilities, ensuring readiness for large-scale deployment. The company is also planning to submit a lower-dose pediatric version (1 mg) to expand access among younger patient populations, reinforcing its long-term lifecycle and regulatory strategy.

Redefining Standards in Anaphylaxis Treatment

The approval of neffy represents a paradigm shift in emergency allergy management, aligning with global healthcare trends focused on improving real-world effectiveness and patient experience. By removing key barriers associated with injectable therapies, this innovation supports earlier intervention, improved adherence, and enhanced clinical outcomes.

As pharmaceutical companies continue to prioritize patient-friendly drug delivery systems, neffy sets a new benchmark in emergency therapeutics and demonstrates how innovation can directly translate into improved safety and quality of care for patients at risk of life-threatening allergic reactions.

Source: ARS Pharma press release